



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Confirmation No. TBD
)	
Eduardo MARBAN <i>et al.</i>)	Group Art No. TBD
)	
Serial No.: 10/593,814)	Examiner: TBD
)	
Filed: September 22, 2006)	Atty. Docket No: 001107.00623
)	
For: Preventing Arrhythmias Associated With)	
Cell Transplantation)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450

Submitted herewith is one (1) sheet of Form PTO-1449. It is respectfully requested that the Examiner make his/her consideration of each of the listed documents formally of record.

It is believed that no fee is required to ensure consideration of the cited references by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge Deposit Account 19-0733.

Respectfully submitted,

By: Sarah A. Kagan
Sarah A. Kagan
Registration No. 32,141

Dated: December 28, 2006


Banner & Witcoff, Ltd.
Customer No. 22907

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

Complete if Known

Application Number

10/593,814

Filing Date

September 22, 2006

First Named Inventor

Eduardo MARBAN et al.

Art Unit

TBD

Examiner Name

TBD

Attorney Docket Number

001107.00623

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RMK/		P. MENASCHE et al., "Autologous Skeletal Myoblast Transplantation for Severe Postinfarction Left Ventricular Dysfunction," J Am Coll Cardiol. 2003; 41: 1078-83	
		P.C. SMITS et al., "Catheter-Based Intramyocardial Injection of Autologous Skeletal Myoblasts as Primary Treatment of Ischemic Heart Failure: Clinical Experience with 6-Month Follow-Up," J Am Coll Cardiol. 2003; 42: 2063-9.	
		P. MENASCHE, "Skeletal Muscle Satellite Cell Transplantation," Cardiovasc Res. 2003; 58:351-7.	
		D. A. TAYLOR et al., "Regenerating Functional Myocardium: Improved Performance After Skeletal Myoblast Transplantation," Nat Med. 1998; 4:929-33.	
		F. D. PAGANI et al., "Autologous Skeletal Myoblasts Transplanted to Ischemia-Damaged Myocardium in Humans," Histological Analysis of Cell Survival and Differentiation, J Am Coll Cardiol. 2003; 41 :879-88.	
		N. AL ATTAR et al., "Long term (1 year) Functional and Histological Results of Autologous Skeletal Muscle Cells Transplantation in Rat, Cardiovasc Res. 2003; 58:142-8.	
		A. A. HAGEGE et al., "Viability and Differentiation of Autologous Skeletal Muscle Grafts in Ischaemic Cardiomyopathy," Lancet. 2003; 361:491-2.	
		H. REINECKE et al., "Electromechanical Coupling Between Skeletal and Cardiac Muscle," Implications for Infarct Repair, J Cell Biol. 2000;149:731-40.	
		B. LEOBON et al., "Myoblasts Transplanted into Rat Infarcted Myocardium are Functionally Isolated from Their Host," Proc Natl Acad Sci USA, 2003; 100:7808-11.	
		D. E. GUTSTEIN et al., "Conduction Slowing and Sudden Arrhythmic Death in Mice with Cardiac-Restricted Inactivation of aConnexin43, Circulation Research. 2001;88:333-339.	
		K. SUZUKI et al., "Overexpression of Connexin 43 in Skeletal Myoblasts: Relevance to Cell Transplantation to the Heart," J Thorac Cardiovasc Surg. 2001; 122:759-66.	
/RMK/		Qin Hong et al., "Retroviral Delivery of Connexin Genes to Human Breast Tumor Cells Inhibits in Vivo Tumor Growth by a Mechanism That is Independent of Significant Gap Junctional Intercellular Communication," Journal of Biological Chemistry. 2002; 277:29132.	

Examiner
Signature

/Robert M Kelly/

Date
Considered

4/1/10